Biotech
Cellular Treatment Outperforms Chemo in Cancer Models
Von KI berichtet Fakten geprüft
A new treatment tested in brain organoids with glioblastoma outperformed chemotherapy and dramatically reduced tumors in mice. Human trials are upcoming. The approach also explores stem cell stimulation and aging cell rejuvenation for broader immunotherapy applications.
Summit's Lung Cancer Drug Shows Promise
Biotech company Summit announced promising results from its lung cancer drug in recent trials. The drug demonstrated potential efficacy in treating advanced cases, marking a step forward in oncology treatments. Further studies are planned to confirm these findings.
Stem Cell EVs Aid Tissue Repair
Von KI berichtet Fakten geprüft
StemDAO is developing therapies using extracellular vesicles from stem cells to address soft tissue injuries, cognitive decline, and aging. Clinical data shows benefits in cognition, skin health, and inflammation reduction. This approach triggers natural regeneration without surgery.
Beyond Meat investor eyes ETHZilla after stock rally
Dimitri Semenikhin, the retail trader who sparked the recent Beyond Meat stock rally, has announced a new investment in ETHZilla Corporation. The company, formerly a biotech firm known as 180 Life Sciences, recently pivoted to a digital asset treasury focused on ethereum. ETHZilla's shares surged following Semenikhin's disclosure, amid a broader trend of companies adopting crypto treasuries in 2025.
Vaccine Therapy Progress for Brain Tumors
Von KI berichtet Fakten geprüft
Vaccine therapy for malignant glioma is advancing, with calls for expedited approvals to treat this aggressive brain cancer. The approach has potential to save lives and is part of efforts for rare disease treatments. Early results indicate effectiveness without traditional chemo or radiation.